Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors

Brianna E. Vaa, Ayalew Tefferi, Naseema Gangat, Animesh Pardanani, Terra L. Lasho, Christy M. Finke, Alexandra P. Wolanskyj

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Primary myelofibrosis (PMF)-associated pruritus is often severe and requires treatment. Fifty-one patients with bone marrow-proven PMF with associated pruritus were identified from a primary cohort of patients with PMF (n = 566) seen at our institution. We conducted a retrospective review of the clinical characteristics, severity of pruritus, type of treatment, and response of these patients. Thirty-two out of 51 patients (63 %) reported severe PMF-associated pruritus and required a total of 108 treatment episodes, with complete response (CR), partial response (PR) and no response (NR) observed in 22, 23, and 55 % of episodes, respectively. The most common treatment categories included JAK inhibitors (n = 19), anti-depressants (n = 18), and antihistamines (n = 17). Highest CR rates were observed in patients treated with a JAK inhibitor (53 %) and immunomodulatory drugs (IMiDS (50 %)). Emerging targeted therapies may result in better symptom control and higher response rates in patients suffering from severe PMF-associated pruritus.

Original languageEnglish (US)
Pages (from-to)1185-1189
Number of pages5
JournalAnnals of hematology
Issue number7
StatePublished - Jun 1 2016


  • JAK inhibitors
  • Primary myelofibrosis
  • Pruritus
  • Treatment options

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors'. Together they form a unique fingerprint.

Cite this